Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Prospective Randomised Clinical Trial of VMX-C001 vs Usual Pharmacological Care in Patients Receiving a FXa Direct Oral Anticoagulant (FXa DOAC) Who Require Urgent Surgery or Other Invasive Procedure That is Associated With a High Risk of Bleeding, With or Without Planned Administration of Heparin (EQUILIBRIX-S)

NCT07288489 is registered in ClinicalTrials.gov with VarmX B.V. as lead sponsor.

NCT NCT07288489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Prospective Randomised Clinical Trial of VMX-C001 vs Usual Pharmacological Care in Patients Receiving a FXa Direct Oral Anticoagulant (FXa DOAC) Who Require Urgent Surgery or Other Invasive Procedure That is Associated With a High Risk of Bleeding, With or Without Planned Administration of Heparin (EQUILIBRIX-S)
Lead sponsor
VarmX B.V.
Phase
Phase 3
Overall status
Recruiting
Start date
August 18, 2026
Completion date
January 31, 2031
Enrollment
800 (estimated)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

blood loss, surgical, coagulation disorder